Post on 14-Apr-2018
7/30/2019 Surv Corpus Uteri
1/10
National Cancer Institute 123 SEER Survival Monograph
INTRODUCTION
Cancer of the endometrium, the lining of the uterus, is
the most common gynecologic malignancy. It is the 4th
leading cancer in women (behind breast, lung and colorec-
tal) and accounts for approximately 6% of all cancers in
women (1). Uterine sarcomas are rare, comprising less
than 8% of all uterine malignancies. These tumors ariseprimarily from two distinct tissues: 1) leiomyosarcoma
from myometrial muscle and 2) mesodermal (Mullerian)
and stromal sarcomas from endometrial epithelium.
MATERIALS AND METHODS
The NCI contracts with medically-oriented, nonprofit in-
stitutions located in specific geographic areas to obtain
data on all cancers diagnosed in residents of the SEER
geographic areas. SEER collects data on all invasive
and in situ cancers except basal cell and squamous cell
carcinomas of the skin (of non-genital anatomic sites) and
in situ carcinomas of the uterine cervix. SEER activelyfollows all previously diagnosed patients on an annual
basis to obtain vital status allowing the calculation of
observed and relative survival rates.
This analysis is based on data from 12 SEER geographic
areas which collectively cover about 14% of the total US
population. The areas are the States of Connecticut, Iowa,
New Mexico, Utah, and Hawaii; the metropoli tan areas of
Detroit, Michigan; Atlanta, Georgia; San Francisco, San
Jose, and Los Angeles, California; Seattle, Washington;
and 10 counties in rural Georgia. Los Angeles contributeddata for diagnosis years 1992 to 2001, all other areas for
1988-2001.
Between 1988-2001, there were 57,769 cases of cancer
of the corpus uteri diagnosed in SEER. Note: cancer of
the corpus uteri does not include uterus, not otherwise
specified (NOS). The following were excluded from the
analysis: patients for whom cancer of the corpus uteri
was not the first primary, cases identified through autopsy
or death certificate only, persons of unknown race, alive
cases with no survival time, patients less than 20 years
old, cases of in situ cancers, cases without microscopic
confirmation, and carcinoids. Unlike other chapters, sar-comas were included. After these exclusions, 48,642 adult
cases remained for analysis (see Table 15.1).
Carol L. Kosary
Chapter 15Cancer of the Corpus Uteri
Table 15.1: Cancer of the Corpus Uteri: Number of Cases and Exclusions by Reason, 12 SEER Areas, 1988-2001
Number Selected/Remaining Number Excluded Reason for Exclusion/selection
57,769 0 Select 1988-2001 diagnosis (Los Angeles for 1992-2001 only)50,570 7,199 Select first primary only
50,453 117 Exclude death certificate only or at autopsy
50,144 309 Exclude unknown race
50,083 61 Exclude alive with no survival time
50,073 10 Exclude children (Ages 0-19)
48,877 1,196 Exclude in situ cancers
48,661 216 Exclude no or unknown microscopic confirmation
48,642 19 Exclude carcinoids
7/30/2019 Surv Corpus Uteri
2/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 124 SEER Survival Monograph
RESULTS
Age and Race
Of the 48,642 cases, 63.5% of adults with cancer of the
corpus uteri were diagnosed after age 60 years and older
(Table 15.2). Over 50% were between the ages of 60-79
years. Eighty-seven percent were white. Little differenceexists in age distribution for white and black women,
but the age distribution for women of other races was
younger.
For all women, relative survival declines with age. In
women 20-49 year of age, the 5-year relative survival
rate is 90% compared to 87% in women 50-69 and 79%
in women aged 70 and older. Survival is also lower for
black women compared to white women in all age groups
presented (Table 15.3). The largest survival difference
was for age group 70+ where the 5-year relative survival
rate was 49% for black females compared to 81% forwhite females.
Geographic Location
There is little variation in survival by geographic area.
Five-year relative survival rates in the 12 SEER areas
presented in this study ranged from 89% in Seattle to
81% in Detroit (Table 15.4).
Histology
Distribution by histology is presented in Table 15.5. Tu-
mors classified as adenocarcinoma comprise over 90% ofall cancers of the corpus uteri. Of these, the most common
subclassification was adenocarcinoma, NOS, which ac-
counted for slightly more than 53% of all adenocarcino-
mas registered. Endometrioid adenocarcinoma was the
next most common adenocarcinoma, at 30% followed by
papillary serous (3.5%), adenosquamous (2.9%), papillary
(2.3%), squamous metaplasia (2.6%), mucinous (1.9%),
and clear cell (1.6%).
Sarcomas and Other Specified Types comprise 7.7% of
the total. Of these 34% are Mullerian, 25% leiomyosar-
coma, 19% carcinosarcoma and 16% endometrial stromal
sarcoma.
The 5-year relative survival rates vary greatly by histology
from over 90% for adenocarcinoma, NOS, mucinous/mucin
producing adenocarcinoma, and endometrioid adenocar-
cinoma to less than 50% for papillary serous adenocarci-
noma, leiomyosarcoma, and Mullerian mixed tumor.
Staging
Uterine corpus cancer staging by the Federation Interna-
tionale de Gynecologie et dObstetrique (FIGO) and the
American Joint Committee on Cancer (AJCC) are in the
AJCCManual for Staging of Cancer, 3rd edition (2):Stage I tumor confined to the corpus uteri.
Stage IA: tumor limited to endometrium
Stage IB: tumor invades less than one half of the
myometrium
Stage IC: tumor invades one half or more of the myometrium
Stage II tumor invades the cervix, but has not extended
outside the uterus.
Stage III tumor extends outside of the uterus but is confined
to the true pelvis.
Stage IV tumor involves the bladder or bowel mucosa or
has metastasized to distant sites (including abdominallymph nodes other than para-aortic, and/or inguinal lymph
nodes; excludes metastasis to vagina, pelvic serosa, or
adnexa).
Since the emphasis is on extension, a SEER modifiedversion of stage was used in which positive lymph nodes
went to N1 and Stage III but unknown lymph node in-
volvement was ignored, i.e. treated like N0.
ADENOCARCINOMA
Stage
Table 15.6 and Figure 15.1 show the contrast across stage
over time since diagnosis. In stages II-IV, the steepest
declines in survival are observed within 1-3 years of di-
agnosis. Survival continues to decline throughout the 10
years observed for stage III.
Age and Stage
Of the 44,059 cases of adenocarcinoma, enough infor-
mation to establish stage at diagnosis was available for
42,589 (96.7%). Across all age groups, 70% or more of
all cancers were diagnosed in Stage I. The percent of
tumors limited to the endometrium or invading less than
half of the myometrium (Stages IA and IB) declines from
64% in women age 20-49 to 46% in women 70 and over.
Stage IV disease rises from 5% in women age 20-49 to
9% in women 70 and over. (Table 15.7).
Across all age groups, a slight survival advantage is seen
in Stage IA and IB disease compared to Stage IC. For all
women, this translates to 99% 5-year survival for Stages
IA & IB versus 92% for stage IC. Median survival time
is over 10 years for all ages within Stage I, with the
exception of women aged 70 and older diagnosed with
Stage IC, where median survival time was found to be
7/30/2019 Surv Corpus Uteri
3/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 125 SEER Survival Monograph
Table 15.4: Cancer of the Corpus Uteri: Number and Distribution of Cases and 1-, 2-, 3-, 5-, 8-, & 10-Year Relative Survival Rates(%) by SEER Geographic Area, Ages 20+, 12 SEER Areas, 1988-2001
Relative Survival Rate (%)
SEER Geographic Area Cases Percent 1-Year 2-Year 3-Year 5-Year 8-Year 10-Year
Total 48,642 100.0 93.5 89.5 87.0 84.7 83.1 82.6
Atlanta and Rural Georgia 2,646 5.4 93.1 88.3 85.4 82.9 80.1 79.6
Atlanta (Metropolitan) - 1988+ 2,508 5.2 93.0 88.1 85.5 82.9 80.3 79.8
Rural Georgia - 1988+ 138 0.3 95.0 91.1 84.1 81.5 76.8 72.1
California
Los Angeles - 1992+ 7,978 16.4 92.1 87.2 84.6 81.7 80.4 79.0
Greater Bay Area 8,591 17.7 93.8 89.7 87.6 85.6 83.8 83.6
San Francisco-Oakland SMSA - 1988+ 5,882 12.1 93.8 89.6 87.5 85.9 83.6 83.2San Jose-Monterey - 1988+ 2,709 5.6 93.8 90.1 87.7 85.0 84.3 84.0
Connecticut - 1988+ 6,198 12.7 94.6 90.8 88.7 86.5 85.2 84.2
Detroit (Metropolitan) - 1988+ 6,451 13.3 91.8 86.7 83.6 81.0 79.2 78.4
Hawaii - 1988+ 1,585 3.3 93.9 89.7 87.4 84.1 81.5 81.0
Iowa - 1988+ 5,266 10.8 93.8 90.2 87.7 85.7 84.6 84.1
New Mexico - 1988+ 1,837 3.8 94.4 91.0 87.8 85.4 82.8 82.6
Seattle (Puget Sound) - 1988+ 5,860 12.0 95.4 92.6 90.6 89.2 88.1 88.1
Utah - 1988+ 2,230 4.6 94.0 90.4 88.0 85.1 83.2 82.1
Table 15.2: Cancer of the Corpus Uteri: Age (20+) and Race Distributions, 12 SEER Areas, 1988-2001
Total White Black Other
Age Group (Years) Cases Percent Cases Percent Cases Percent Cases Percent
Total 48,642 100.0 42,220 100.0 3,065 100.0 3,357 100.0
20-29 218 0.4 154 0.4 25 0.8 39 1.2
30-39 1,542 3.2 1,145 2.7 146 4.8 251 7.5
40-49 5,254 10.8 4,198 9.9 309 10.1 747 22.3
50-59 10,740 22.1 9,226 21.9 576 18.8 938 27.9
60-69 13,816 28.4 12,032 28.5 1,016 33.1 768 22.9
70-79 11,972 24.6 10,792 25.6 700 22.8 480 14.3
80+ 5,100 10.5 4,673 11.1 293 9.6 134 4.0
Table 15.3: Cancer of the Corpus Uteri: Number of Cases, Median Survival Time (Months) and 5-Year Survival Rates (%) by Race
and Age (20+), 12 SEER Areas, 1988-2001
Median Survival
Time
5-Year Survival Rates (%)
Race/Age Cases (Months) Observed Expected Relative
All Races, 20+ 48,642 > 120 75.1 88.6 84.7
White, 20+ 42,220 > 120 76.3 88.2 86.4Black, 20+ 3,065 72.1 53.2 86.1 61.8
All Races, 20-49 7,014 > 120 88.7 98.9 89.7
White, 20-49 5,497 > 120 90.0 98.9 91.0
Black, 20-49 480 > 120 76.5 97.8 78.1
All Races, 50-69 24,556 > 120 82.1 94.3 87.0
White, 50-69 21,258 > 120 83.9 94.4 88.9
Black, 50-69 1,592 99.8 57.4 90.6 63.4
All Races, 70+ 17,072 89.0 59.8 76.1 78.6
White, 70+ 15,465 92.2 61.3 76.0 80.6
Black, 70+ 993 28.4 35.6 73.3 48.6
7/30/2019 Surv Corpus Uteri
4/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 126 SEER Survival Monograph
Table 15.5: Cancer of the Corpus Uteri: Number and Distribution of Cases and 5-Year Relative Survival Rate (%) by Histology,
Ages 20+, 12 SEER Areas, 1988-2001
Histology ICD-O Code Cases Percent
5-Year
RSR (%)
All Values 8000-9989 48,642 100.0 84.7
Epidermoid 8051-8130 132 0.3 61.1
Adenocarcinoma 8050,8140-8147,8160-8162,8180-8221,8250-8506,8520-
8550,8560,8570-8573,8940-8941 44,059 90.6 87.9
Adenocarcinoma, NOS* 8140 23,489 48.3 90.8
Papillary 80508260 1,035 2.1 70.3
Clear Cell 8310 704 1.4 64.8
With Squamous Metaplasia 8570 1,151 2.4 93.8
Mucinous & MucinProducing 8480-8481 824 1.7 95.0
Adenosquamous 8560 1,256 2.6 74.0
Endometrioid 8380 13,258 27.3 91.2
Papillary Serous 8460 1,555 3.2 44.7
All Other Adenocarcinoma 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-
8379,8381-8459,8461-8479,8482-8506,8520-8550,8571-
8573,8940-8941 787 1.6 68.5
Other Specified Carcinomas 8030-8045,8150-8155,8170-8171,8230-8248,8510-8512,8561-8562,8580-8671 24 0.0 ~
Carcinoma, NOS* 8010-8022 608 1.2 58.4
Sarcomas and Other
Specified Types
8680-8713,8720-8790,8800-8920,8930-8933,8950-8982,8990-
8991,9000-9030,9040-9055,9060-9110,9120-9134,9141-
9340,9350-9364,9380-9512,9530-9581 3,742 7.7 53.3
Leiomyosarcoma 8890-8897 939 1.9 48.2
Carcinosarcoma 8933,8980-8981 706 1.5 53.7
Endometrial Stromal 8930 610 1.3 74.6
Mullerian 8950-8951 1,264 2.6 45.3
All Other 8680-8713,8720-8790,8800-8889,8898-8920,8931-
8932,8935,8952-8979,8982,8990-8991,9000-9030,9040-
9055,9060-9110,9120-9134,9141-9340,9350-9364,9380-9512,-
9530-9581 230 0.5 53.9Unspecified 8000-8004 70 0.1 55.1
~ Statistic not displayed due to less than 25 cases.
* NOS: Not Otherwise Specified
Table 15.6: Adenocarcinoma of the Corpus Uteri: Number and Distribution of Cases and 1-, 2-, 3-, 5-, 8-, & 10-Year Relative
Survival Rates (%) by AJCC Stage (SEER modified 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
AJCC Stage Cases Percent
Relative Survival Rate(%)
1-Year 2-Year 3-Year 5-Year 8-Year 10-Year
Total 44,059 100.0 95.2 92.1 89.9 87.9 86.4 86.0
Stage I 33,179 75.3 99.7 99.1 98.3 97.4 96.3 95.7
IA 9,528 21.6 99.9 99.8 99.5 99.3 99.0 99.0
IB 15,084 34.2 100.0 100.0 99.7 99.2 98.3 97.5
IC 4,142 9.4 99.1 97.2 95.0 91.9 88.4 86.2
I NOS* 4,425 10.0 97.8 95.8 93.8 92.1 90.5 90.2
Stage II 3,475 7.9 94.8 89.7 85.1 80.2 77.2 76.5
Stage III 2,651 6.0 87.5 75.8 68.2 59.6 53.4 50.5
Stage IV 3,284 7.5 61.5 44.4 35.8 28.6 25.3 25.3
Unknown/Unstaged 1,470 3.3 83.5 72.5 66.8 63.5 60.3 59.6
* NOS: Not Otherwise Specified
7/30/2019 Surv Corpus Uteri
5/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 127 SEER Survival Monograph
Table 15.8: Adenocarcinoma of the Corpus Uteri: Number of Cases and 5-Year Relative Survival Rates (RSR) (%) by AJCC Stage
(SEER modified 3rd edition) and Age (20+), 12 SEER Areas, 1988-2001
AJCC Stage
Total 20-49 50-69 70+
Cases
5-YearRSR
(%)
MedianSurvival
Time
(Months) Cases
5-YearRSR
(%)
MedianSurvival
Time
(Months) Cases
5-YearRSR
(%)
MedianSurvival
Time
(Months) Cases
5-YearRSR
(%)
MedianSurvival
Time
(Months)
Total 44,059 87.9 > 120 5,931 93.2 > 120 22,606 89.7 > 120 15,522 82.5 96.5
Stage I 33,179 97.4 > 120 4,604 98.2 > 120 17,679 97.2 > 120 10,896 97.8 > 120
IA 9,528 99.3 > 120 2,040 98.9 > 120 5,224 99.4 > 120 2,264 99.3 > 120
IB 15,084 99.2 > 120 1,723 98.1 > 120 8,500 98.2 > 120 4,861 100.0 > 120
IC 4,142 91.9 > 120 193 94.8 > 120 1,789 90.4 > 120 2,160 93.3 107.4
I NOS 4,425 92.1 > 120 648 97.4 > 120 2,166 93.8 > 120 1,611 86.6 102.4
Stage II 3,475 80.2 > 120 481 91.1 > 120 1,592 84.1 > 120 1,402 70.3 64.7
Stage III 2,651 59.6 66.6 352 76.0 > 120 1,250 65.3 102.3 1,049 45.5 32.9
Stage IV 3,284 28.6 17.8 317 46.0 42.4 1,539 31.9 21.2 1,428 19.3 12.6
Unknown/
Unstaged 1,470 63.5 62.8 177 83.3 > 120 546 77.3 > 120 747 42.2 23.3
Table 15.7: Adenocarcinoma of the Corpus Uteri: Distribution by AJCC Stage (SEER modified 3rd edition) and Age (20+),
12 SEER Areas, 1988-2001
AJCC Stage
Age (Years)
Total 20-49 50-69 70+
Cases Percent Cases Percent Cases Percent Cases Percent
Total 44,059 100.0 5,931 100.0 22,606 100.0 15,522 100.0
Stage I 33,179 75.3 4,604 77.6 17,679 78.2 10,896 70.2
IA 9,528 21.6 2,040 34.4 5,224 23.1 2,264 14.6IB 15,084 34.2 1,723 29.1 8,500 37.6 4,861 31.3
IC 4,142 9.4 193 3.3 1,789 7.9 2,160 13.9
I NOS* 4,425 10.0 648 10.9 2,166 9.6 1,611 10.4
Stage II 3,475 7.9 481 8.1 1,592 7.0 1,402 9.0
Stage III 2,651 6.0 352 5.9 1,250 5.5 1,049 6.8
Stage IV 3,284 7.5 317 5.3 1,539 6.8 1,428 9.2
Unknown/Unstaged 1,470 3.3 177 3.0 546 2.4 747 4.8
* NOS: Not Otherwise Specified
90
100
70
80
ate(%)
50
60
urviva
lR
30
40
elativeS
10
IA IB IC II III IV
AJCC Stage
20-49 50-69 70+
100
80
lRate(% IA
IB
60
eSurv
ival
IC
40Relati
III
20
IV
0
0 12 24 36 48 60 72 84 96 108 120
Months after diagnosis
Figure 15.2: Adenocarcinoma of the Corpus Uteri: 5-Year
Relative Survival Rate (%) by AJCC Stage (SEER modied 3rd
edition) and Age Group (20+), 12 SEER Areas, 1988-2001
Figure 15.1: Adenocarcinoma of the Corpus Uteri: Relative
Survival Rate (%) by AJCC Stage (SEER modied 3rd edition),
Ages 20+, 12 SEER Areas, 1988-2001
7/30/2019 Surv Corpus Uteri
6/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 128 SEER Survival Monograph
107 months. A survival differential across age exists for
Stages II-IV. Women ages 20-49 diagnosed with Stage
II disease experience a 5-year relative survival rate of
91%. This falls to 84% for women age 50-69 and 70%
for women ages 70 and older. For Stage III, survival is
76% in women 20-49, 65% in those 50-69 and 45% for
those aged 70 and over. For Stage IV, survival is 46% in
women under 50, 32% in those 50-69 and 19% for thoseaged 70 and over (Table 15.8, Figure 15.2).
Table 15.9: Adenocarcinoma of the Corpus Uteri: Number of Cases and 5-Year Relative Survival Rates (%) by Histology and AJCCStage (SEER modified 3rd edition) , Ages 20+, 12 SEER Areas, 1988-2001
Histology
AJCC Stage
Total I II III IV Unknown/
Unstaged
Cases
5-YearRSR
(%) Cases
5-YearRSR
(%) Cases
5-YearRSR
(%) Cases
5-YearRSR
(%) Cases
5-YearRSR
(%) Cases
5-YearRSR
(%)
Total 44,059 87.9 33,179 97.4 3,475 80.2 2,651 59.6 3,284 28.6 1,470 63.5
Adenocarcinoma, NOS* 23,489 90.8 18,775 98.0 1,602 81.3 965 59.8 1,272 30.1 875 66.6
Papillary 1,035 70.3 634 91.0 107 56.8 80 49.4 162 17.0 52 23.4
Clear Cell 704 64.8 338 88.4 90 67.3 94 47.8 139 17.9 43 54.1
With Squamous Metaplasia 1,151 93.8 952 97.2 82 84.6 47 84.6 46 51.7 24 ~
Mucinous & Mucin Producing 824 95.0 621 99.9 53 95.7 63 83.9 60 43.3 27 73.1
Adenosquamous 1,256 74.0 730 89.9 161 78.4 136 57.0 191 24.8 38 55.1
Endometrioid 13,258 91.2 10,149 98.4 1,149 85.7 904 66.9 727 36.8 329 65.4
Papillary Serous 1,555 44.7 531 73.9 163 55.8 258 33.3 542 18.3 61 34.4
All Other Adenocarcinoma 787 68.5 449 92.5 68 46.7 104 42.5 145 14.5 21 ~
~ Statistic not displayed due to less than 25 cases.
* NOS: Not Otherwise Specified
Figure 15.3: Adenocarcinoma of the Corpus Uteri: 5-Year
Relative Survival Rate (%) by Histology and AJCC Stage (SEER
modied 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
Figure 15.4: Adenocarcinoma of the Corpus Uteri: 5-Year
Relative Survival Rate (%) by Grade and AJCC Stage (SEER
modied 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
(%)
708090
alRate
405060
eSurvi
1020
Relati
IA IB IC II III IV
AJCC Sta e
Grade I Grade II Grade III Grade IV
90100
e(%)
607080
vivalRa
304050
iveSur
010
Rela
AJCC Stage
Adenocarcinoma, NOS Papillary
Mucinous & Mucin Producing Adenosquamous
Endometroid Papillary Serous
Subtype and Stage
Survival by subtype and stage is presented in Table 15.9
and Figure 15.3. A survival disadvantage is seen in tumors
of the papillary serous subtype across all stages. These tu-
mors are histologically similar to those found in the ovary.
Similar but smaller differentials are observed for clear cell
and papillary subtypes. Adenosquamous may have a slightsurvival disadvantage in Stage I. This may be due to more
of these tumors being diagnosed in Stage IC and fewer
in Stage IA (Table 15.10). Tumors exhibiting squamous
metaplasia exhibit higher survival, particularly in stages III
7/30/2019 Surv Corpus Uteri
7/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 129 SEER Survival Monograph
Table 15.10: Stage I Adenocarcinoma of the Corpus Uteri: Distribution by Histology and Detailed AJCC Stage (SEER modified
3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
Histology
AJCC Stage
Total Stage I IA IB IC I NOS
CasesRow
Percent CasesRow
Percent CasesRow
Percent CasesRow
Percent CasesRow
Percent
Total 33,179 100.0 9,528 28.7 15,084 45.5 4,142 12.5 4,425 13.3
Adenocarcinoma, NOS* 18,775 100.0 5,327 28.4 8,352 44.5 2,239 11.9 2,857 15.2Papillary 634 100.0 180 28.4 249 39.3 77 12.1 128 20.2
Clear Cell 338 100.0 107 31.7 140 41.4 42 12.4 49 14.5
With Squamous Metaplasia 952 100.0 277 29.1 461 48.4 101 10.6 113 11.9
Mucinous & Mucin Producing 621 100.0 199 32.0 268 43.2 73 11.8 81 13.0
Adenosquamous 730 100.0 125 17.1 345 47.3 153 21.0 107 14.7
Endometrioid 10,149 100.0 2,944 29.0 4,888 48.2 1,353 13.3 964 9.5
Papillary Serous 531 100.0 193 36.3 211 39.7 69 13.0 58 10.9
All Other Adenocarcinoma 449 100.0 176 39.2 170 37.9 35 7.8 68 15.1
* NOS: Not Otherwise Specified
Table 15.11: Adenocarcinoma of the Corpus Uteri: Number of Cases and 5-Year Relative Survival Rates (%) by AJCC Stage (SEER
modified 3rd edition) and Grade, Ages 20+, 12 SEER Areas, 1988-2001
AJCC Stage
Grade
Total Well
Differentiated
Moderately
Differentiated
Poorly
Differentiated
Anaplastic Unknown
Cases
5-Year
RSR
(%) Cases
5-Year
RSR
(%) Cases
5-Year
RSR
(%) Cases
5-Year
RSR
(%) Cases
5-Year
RSR
(%) Cases
5-Year
RSR
(%)
Total 44,059 87.9 17,429 99.2 15,002 90.8 7,544 64.9 1,294 54.8 2,790 72.9
Stage I 33,179 97.4 15,472 100.0 11,492 97.2 4,061 86.6 557 79.7 1,597 93.0
IA 9,528 99.3 5,517 99.9 2,599 99.2 741 90.9 114 83.3 557 95.3
IB 15,084 99.2 6,631 100.0 5,741 98.7 1,895 92.5 261 88.9 556 95.7
IC 4,142 91.9 1,161 99.4 1,813 95.3 899 77.0 124 63.6 145 88.0
I NOS* 4,425 92.1 2,163 98.4 1,339 89.9 526 75.3 58 60.9 339 85.2
Stage II 3,475 80.2 847 93.1 1,399 84.7 835 66.7 150 51.3 244 68.3
Stage III 2,651 59.6 370 82.7 898 68.0 970 48.3 210 46.4 203 45.0
Stage IV 3,284 28.6 269 59.9 801 45.1 1,426 16.9 323 19.9 465 21.1
Unknown/Unstaged 1,470 63.5 471 79.4 412 63.1 252 36.3 54 38.3 281 62.8
* NOS: Not Otherwise Specified
and IV. Clear cell and papillary types show lower survivalin stages II-IV.
Stage and Grade
Five-year relative survival rates for adenocarcinoma are
shown by tumor grade in Table 15.11 and Figure 15.4.
Within stage, 5-year relative survival rates declined as grade
increases with the exception of poorly differentiated and
anaplastic Stage IV tumors.
Conditional Survival
Five year relative survival rates, conditioned on years since
diagnosis, are presented in Table 15.12 and Figure 15.5.
For stages IC-IV, the probability of surviving the next 5
years increases as time since diagnosis increases. This is
most marked for the stage IV cases. Five year survival
from time of diagnosis is 29%. For those individuals who
survive 1 year post diagnosis, 5-year survival increases
to 43%. This increases to 86% for those individuals who
survived 5 years.
7/30/2019 Surv Corpus Uteri
8/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 130 SEER Survival Monograph
Table 15.12: Adenocarcinoma of the Corpus Uteri: 5-Year Relative Survival Rates (%), Conditioned on Years Since Diagnosis, by
AJCC Stage (SEER modified 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
AJCC Stage
5-Year Relative Survival Rate (%)
Years Since Diagnosis
0 1 2 3 4 5
Total 87.9 91.2 93.9 95.5 96.9 97.4
Stage I 97.4 97.3 97.9 98.1 98.7 98.7
IA 99.3 99.3 99.6 99.6 99.8 99.9
IB 99.2 98.6 99.0 99.0 99.3 99.1
IC 91.9 92.0 92.9 93.3 94.4 94.3
I NOS* 92.1 93.2 94.6 95.7 97.1 97.2
Stage II 80.2 81.6 85.0 89.4 91.1 93.6
Stage III 59.6 64.2 71.0 76.7 80.1 83.0
Stage IV 28.6 43.2 57.8 68.1 78.6 86.0
Unknown/Unstaged 63.5 71.5 79.4 84.2 86.0 87.5
* NOS: Not Otherwise Specified
SARCOMA AND OTHER SPECIFIED TYPES
Subtype and Stage
Of the 3,742 cases of sarcoma and other specified types,
enough information to establish stage at diagnosis was avail-
able for 3,580 (96%). Fifty six percent were diagnosed in
Stage I, while 22% were Stage IV (Table 15.13).
Survival by stage for sarcomas overall is presented in Figure
15.6. Survival by subtype and stage is presented in Table
15.14. Despite some data sparseness in Stage II, it is ob-
served that endometrial stromal tumors experience a better
survival across stage than do either tumors categorized as
leiomyosarcoma, carcinosarcoma, or Mullerian, which had
similar survival rates.
Stage and Grade
Despite data sparseness in well differentiated, within stage,
5-year relative survival declines as grade increases (Table15.15).
Conditional Survival
Five year relative survival, conditioned on years since di-
agnosis, is presented in Table 15.16 and Figure 15.7 for
sarcomas and other specific types. For all stages, the prob-
ability of surviving the next 5 years increased as time since
Figure 15.5: Adenocarcinoma of the Corpus Uteri: 5-Year
Relative Survival Rate (%), Conditioned on Years Since
Diagnosis, by AJCC Stage (SEER modied 3rd edition), Ages
20+, 12 SEER Areas, 1988-2001
100 IA
80
90
ate(%)
IB
60
70
rvivalR IC
II
40lativeS
III
20
RIV
0
0 12 24 36 48 60 72 84 96 108 120
Months after diagnosis
Figure 15.6: Sarcoma and Other Specied Types of Cancer of
the Corpus Uteri: Relative Survival Rates (%) by AJCC Stage
(SEER modied 3rd edition), Ages 20+, 12 SEER Areas, 1988-
2001
90
100
70
80
te(%)
50
60
vivalRa
30
40
tiveSur
10
20Rela
0IA IB IC II III IV
AJCC Stage
0 Years 1 Year 2 Years 3 Years 4 Years 5 Years
7/30/2019 Surv Corpus Uteri
9/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 131 SEER Survival Monograph
Table 15.13: Sarcoma & Other Specified Types of Corpus Uterine Cancer: Number and Distribution of Cases and 1-, 2-, 3-, 5-, 8-,
& 10-Year Relative Survival Rates (%) by AJCC Stage (SEER modified 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
AJCC Stage Cases Percent
Relative Survival Rate (%)
1-Year 2-Year 3-Year 5-Year 8-Year 10-Year
Percent Percent Percent Percent Percent Percent
Total 3,742 100.0 78.4 64.4 58.4 53.3 50.0 49.1
Stage I 2,081 55.6 92.2 81.4 76.3 70.8 66.2 64.5
IA 397 10.6 94.4 90.0 86.4 84.3 81.2 76.0IB 558 14.9 91.1 78.2 73.7 68.2 64.9 63.7
IC 280 7.5 90.7 75.9 69.4 62.1 59.0 56.7
I NOS 846 22.6 92.4 81.3 75.4 68.7 61.7 61.0
Stage II 277 7.4 81.0 56.4 49.7 43.6 39.8 39.0
Stage III 394 10.5 69.7 52.2 45.2 38.8 34.5 33.4
Stage IV 828 22.1 50.1 32.0 23.9 19.8 19.6 19.6
Unknown/Unstaged 162 4.3 62.0 49.2 44.8 39.7 35.9 34.6
* NOS: Not Otherwise Specified
Table 15.14: Sarcoma & Other Specified Types of Corpus Uterine Cancer: Number of Cases and 5-Year Relative Survival Rates
(%) by Histology and AJCC Stage (SEER modified 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
Histology
AJCC Stage
Total I II III IV Unknown/
Unstaged
Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%)
Total 3,742 53.3 2,081 70.8 277 43.6 394 38.8 828 19.8 162 39.7
Leiomyosarcoma 939 48.2 623 60.0 28 35.1 64 27.7 185 14.9 39 51.6
Carcinosarcoma 706 53.7 401 73.7 62 43.3 97 26.2 122 13.6 24 ~
Endometrial Stromal 610 74.6 372 89.8 27 40.0 85 64.3 106 37.0 20 ~
Mullerian 1,264 45.3 570 66.7 147 45.7 132 34.8 353 18.2 62 19.4
All Other 223 53.6 115 74.3 13 ~ 16 ~ 62 21.4 17 ~
~ Statistic not displayed due to less than 25 cases.
Table 15.15: Sarcoma & Other Specified Types of Corpus Uterine Cancer: Number of Cases and 5-Year Relative Survival Rates
(%) by AJCC Stage (SEER modified 3rd edition) and Grade, Ages 20+, 12 SEER Areas, 1988-2001
AJCC Stage
Grade
Total Well Differentiated Moderately
Differentiated
Poorly/
Undifferentiated
Unknown
Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%) Cases
5-Year
Relative
Survival
Rate(%)
Total 3,742 53.3 218 86.1 593 79.2 1,351 35.8 1,580 52.8
Stage I 2,081 70.8 167 92.6 435 84.8 603 54.8 876 69.8
IA 397 84.3 37 96.2 80 88.8 60 71.6 220 82.8
IB 558 68.2 32 88.0 93 84.0 215 58.6 218 66.7
IC 280 62.1 10 ~ 48 84.6 118 47.6 104 63.3
I NOS* 846 68.7 88 90.4 214 83.1 210 49.9 334 64.4
Stage II 277 43.6 8 ~ 26 78.6 124 36.0 119 39.2
Stage III 394 38.8 14 ~ 59 68.6 177 28.2 144 35.8
Stage IV 828 19.8 20 ~ 58 47.9 407 13.2 343 20.7
Unknown/Unstaged 162 39.7 9 ~ 15 ~ 40 9.1 98 44.3
~ Statistic not displayed due to less than 25 cases.
* NOS: Not Otherwise Specified
7/30/2019 Surv Corpus Uteri
10/10
Chapter 15 Cancer of the Corpus Uteri
National Cancer Institute 132 SEER Survival Monograph
Table 15.16: Sarcoma & Other Specified Types of Corpus Uterine Cancer: 5-Year Relative Survival Rates (%), Conditioned on
Years Since Diagnosis, by AJCC Stage (SEER modified 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
AJCC Stage
5-Year Relative Survival Rate(%)
Years Since Diagnosis
0 1 2 3 4 5
Total 53.3 64.8 77.8 83.2 87.2 89.5
Stage I 70.8 73.8 82.6 85.6 88.2 90.0
IA 84.3 87.7 91.3 93.3 91.6 90.3
IB 68.2 72.2 83.2 86.3 88.3 91.0
IC 62.1 64.9 77.2 84.1 89.5 90.1
I NOS* 68.7 70.6 78.4 81.1 84.9 88.2
Stage II 43.6 53.1 71.1 76.1 83.1 86.5
Stage III 38.8 51.3 66.7 72.8 77.7 82.9
Stage IV 19.8 38.3 59.6 80.8 91.4 95.4
Unknown/Unstaged 39.7 56.5 67.1 69.9 73.7 74.5
* NOS: Not Otherwise Specified
older women is compounded by advanced stage. In later
stages, particularly stages III and IV, survival declinesrapidly over time since diagnosis.
Overall, all histologies in stage I had a favorable 5-year
survival. The papillary serous histology had the worst
survival across all stages, while papillary metaplasia had
the highest survival in stages II-IV. In the group of sar-
coma histologies, endometrial stromal sarcomas had a
better survival across stage than other sarcomas.
Across all stages, survival declined with advanced stage
of disease, with the exception of poorly differentiated
and anaplastic tumors where there is little difference in
survival for adenocarcinomas.
REFERENCES
1. American Cancer Society. Cancer Facts and Figures 2006.
Atlanta: American Cancer Society, 2006.
2. Beahrs, OH, Henson DE, Hutter RVP, Myers MH (eds).
AJCC Cancer Staging Manual, Third edition. American Joint
Committee on Cancer. Philadelphia: Lippincott, 1988.
Figure 15.7: Sarcoma and Other Specied Types of Cancer
of the Corpus Uteri: 5-Year Relative Survival Rate (%),
Conditioned on Years Since Diagnosis, by AJCC Stage (SEER
modied 3rd edition), Ages 20+, 12 SEER Areas, 1988-2001
90
100
70
80
ate(%)
50
60
rvivalR
30
40
ativeS
10
20Rel
0
IA IB IC II III IV
AJCC Stage
0 Years 1 Year 2 Years 3 Years 4 Years 5 Years
diagnosis increased. This is most marked for the stage IV
cases. Five year survival from time of diagnosis was 20%.
For those individuals who survived 1 year post diagnosis,
5-year survival increased to 38%. This increased to 91%
for those individuals who survived 4 years.
DISCUSSION
Survival is lower for blacks compared to whites regardless
of age, and is most pronounced in women over 70 years of
age. The majority of corpus uteri tumors are adenocarcino-
mas. Of these, more than 70% are diagnosed in stage I and
have a median survival greater than 10 years for women
of all age groups, except in women over 70 years of age
with stage IC where the median survival is slightly less
than 10 years. There exists a differential in survival by age
and across stage of disease II-IV. The poorer survival in